Reuters logo
BRIEF-RIGEL PHARMACEUTICALS SAYS FOSTAMATINIB MEETS PRE-SPECIFIED GOAL IN STAGE 1 OF AIHA PHASE 2 STUDY
2017年10月3日 / 中午11点39分 / 15 天前

BRIEF-RIGEL PHARMACEUTICALS SAYS FOSTAMATINIB MEETS PRE-SPECIFIED GOAL IN STAGE 1 OF AIHA PHASE 2 STUDY

Oct 3 (Reuters) - Rigel Pharmaceuticals Inc:

* FOSTAMATINIB MEETS PRE-SPECIFIED PRIMARY ENDPOINT IN STAGE 1 OF AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA) PHASE 2 STUDY

* RIGEL PHARMACEUTICALS INC - ‍TWO DEATHS WERE REPORTED DURING TRIAL DUE TO NON-TREATMENT RELATED SERIOUS ADVERSE EVENTS​

* RIGEL PHARMACEUTICALS INC - ‍SAFETY PROFILE WAS CONSISTENT WITH EXISTING FOSTAMATINIB SAFETY DATABASE​

* SAYS ‍ON A TOP-LINE, PRELIMINARY BASIS, PHASE 2 STUDY HAS ACHIEVED PRE-SPECIFIED PRIMARY EFFICACY ENDPOINT FOR STAGE 1​

* RIGEL PHARMACEUTICALS INC - ‍RIGEL INTENDS TO BEGIN ENROLLMENT FOR STAGE 2 OF STUDY IN WHICH 20 PATIENTS WILL BE ENROLLED UNDER SAME PROTOCOL​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below